Scholar Rock (NASDAQ:SRRK) Announces Quarterly Earnings Results

Scholar Rock (NASDAQ:SRRK) released its quarterly earnings data on Tuesday. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04, FiscalAI reports. The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.30 million. During the same period last year, the company earned ($0.90) EPS.

Here are the key takeaways from Scholar Rock’s conference call:

• ISEMBYLD’s U.S. launch showed broad early demand: enrollments came from across the country, included treatment-naive patients as well as children and adults, and reached more than one-third of the top 140 SMA treatment centers within six weeks.
• Access delays are likely to push many initial infusions into 2027. The company said prescription-to-infusion timelines can exceed 60–90 days as patients navigate prior authorization, payer policies, and hospital formularies; an ISEMBYLD-specific J-code is expected April 1, 2027.
• Global regulatory progress advanced: apitegromab’s European application was resubmitted and validated, with a CHMP opinion expected in the first half of 2027, while Japan accepted its application for priority review, supporting a potential launch near year-end 2027.
• The company strengthened its financial position with a $205 million agreement to sell its priority review voucher. Scholar Rock reported $413.6 million in cash, equivalents, and marketable securities at quarter-end and said it does not need an equity offering at this time.
• Pipeline programs continued to progress: dosing began in the phase II FORGE study of apitegromab in FSHD, enrollment is ongoing in the under-two OPAL study, and SRK-439 phase I dosing is progressing, with top-line data expected by year-end and an update planned for early 2027.

Scholar Rock Trading Down 5.7%

Shares of NASDAQ SRRK traded down $2.94 during midday trading on Tuesday, hitting $48.62. The company’s stock had a trading volume of 372,536 shares, compared to its average volume of 1,456,550. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77. The business’s 50 day moving average is $47.01 and its two-hundred day moving average is $48.22. Scholar Rock has a 12-month low of $28.97 and a 12-month high of $61.76. The firm has a market cap of $5.92 billion, a P/E ratio of -14.11 and a beta of 0.78.

Insider Transactions at Scholar Rock

In other Scholar Rock news, Director Srinivas Akkaraju acquired 146,970 shares of the business’s stock in a transaction on Monday, October 26th. The shares were bought at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the transaction, the director directly owned 6,380,517 shares of the company’s stock, valued at $265,365,702.03. The trade was a 2.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 10.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

SRRK has been the subject of a number of research reports. Piper Sandler increased their target price on Scholar Rock from $60.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, September 15th. Truist Financial boosted their price target on shares of Scholar Rock from $76.00 to $77.00 and gave the stock a “buy” rating in a research report on Thursday, September 24th. BMO Capital Markets upped their price target on shares of Scholar Rock from $76.00 to $84.00 and gave the company an “outperform” rating in a research note on Monday, September 14th. Wedbush reiterated an “outperform” rating and set a $64.00 price objective on shares of Scholar Rock in a research report on Tuesday, September 15th. Finally, UBS Group reissued a “buy” rating on shares of Scholar Rock in a research note on Tuesday, September 15th. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $67.67.

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation.

The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.

Scholar Rock was founded in 2012.